Nutrition and Energy Restriction for Cancer Prevention

Obesity Clinical Trial

— HELENA  

Official title:

Healthy Nutrition and Energy Restriction as Cancer Prevention Strategies: a Randomized Controlled Intervention Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02449148
• Other study ID #: DKFZ Study_ID 670
• Status: Completed
• Phase: N/A
• Start date: May 2015
• Est. completion date: May 2017

Study information

• Verified date: December 2021
• Source: German Cancer Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the effect of intermittent calorie restriction versus continued calorie restriction on weight loss, gene expression profile of subcutaneous adipose tissue and abdominal fat distribution.

Description:

Since obesity has become a major public health concern appropriate strategies are needed in order to reduce obesity-related health risks in later life span. Obesity is one of the main risk factors not only for diabetes and cardiovascular diseases, but also for several types of cancer. Several key mechanisms, which may link obesity, metabolic dysregulation and cancer risk, such as obesity-driven inflammation, altered adipokine, growth factor and sex hormone signaling, and changes in the microbiota have been identified. Various studies have shown that continuous calorie restriction (CCR) and exercise are effective strategies to enforce weight-loss and improve biomarker profiles. Intermittent calorie restriction (ICR) as a novel strategy might induce favorable metabolic changes and lead to higher compliance rates. The concept of this diet regime is very simple e.g. 2 days/week of fasting following a standardized diet covering 25 % of energy needs and 5 days/week of ad libitum consumption. To verify the effectiveness of ICR as an alternative weight loss strategy to CCR controlled intervention trials are required. Although both CCR and ICR induce a negative energy balance, the metabolic effect on human physiology might differ. Within the HELENA-study 50 non-smoking adults (men and women aged 35 to 65 years) with an BMI ≥ 25 kg/m² and ≤ 40 kg/m² will be randomly assigned to each of the intervention arms: (1) ICR arm (2 day/week fasting, i.e. 25% energy intake, energy intake of 100% on 5 days/week leading to a weekly average energy intake of ~80%) (2) CCR arm (daily energy intake of 80%) and 3) control arm (general advice on healthy nutrition). The trial will last 1 year, with an intervention phase of 12 weeks (weeks 0-12; intervention; close contact with participants), followed by a maintenance phase (weeks 13-24; maintenance; regular, but less frequent contact with participants) and a follow-up phase (weeks 25-52). Biological specimens will be collected as follows: Baseline (T0, week 1): Blood, urine, stool and subcutaneous adipose tissue samples; After 3 months (T1, week 13): Blood, urine, stool and subcutaneous adipose tissue samples; After 6 months (T2, week 25): Blood, urine, and stool; After 12 months (T3, week 52): Blood and urine; Magnet resonance tomography imaging (MRI, at T0, T1 and T3) and lifestyle assessments (nutrition behavior, physical activity and quality of life, T0-T3) will be performed to unravel the link to fat distribution, metabolic changes, health and lifestyle. The primary objective of the three-arm randomized controlled intervention trial is to investigate the effect of nutrition intervention on body weight and gene expression profile in subcutaneous adipose tissue of overweight and obese individuals. We hypothesize that better compliance rates will be achieved by the ICR rather than by the CCR group and that ICR will show a higher sustainability with respect to weight loss, weight maintenance, and biomarker profiles. The purpose of this study is further to analyze if the nutrition interventions and associated weight loss have different effects on abdominal fat distribution and liver fat content. The statistical analysis will be carried out by using the SAS statistical software [SAS Institute Inc., Cary, NC, USA] or comparable software. Descriptive statistics, correlations and univariate analyses will be used to get insight on general characteristics of participants in the intervention groups. For the primary objective, two sided t-test and ANCOVA modelling will be performed to investigate whether changes in gene expression levels are affected by nutrition intervention. Comparisons between two groups (e.g. ICR and CCR or CCR/ICR and control group) will be carried out using t-tests and parallel comparison across the three groups will be carried out using ANCOVA models. Where applicable, the analyses will include adjustments for confounders, specially age and gender. Likewise, stratified analysis will be carried out as necessary. ANCOVA models will be performed to evaluate the effects of nutrition intervention on biomarker profiles, adjusted by strata age and gender. Similar evaluations will be performed for fat distribution patterns, quality of life, physical activity and nutrition patterns. In addition, correlation and linear regression analyses will be performed to measure effects of weight-loss, gene expression levels and metabolic profiles, controlled by nutrition intervention group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• Women and men aged 35 to 65 years
• Overweight or obese (BMI = 25 kg/m2 = 40 kg/m2 )
• German speaking
• Non- smoker
• Provision of written informed consent

Exclusion Criteria:

• Not able to understand and sign the informed consent form in person
• Already diagnosed diabetes
• HbA1c = 6.5 % and/or fasting plasma glucose > 125 mg/dl
• History of cancer within the past 10 years
• Risk of bleeding disorders (e.g. Marcumar intake)
• Current or history of eating disorders (bulimia, anorexia, binge-eating)
• Pregnant or lactating during the past 12 months
• Increased or decreased thyroid-stimulating hormone in baseline blood check
• Already diagnosed hepatic dysfunction and/or increased or decreased ?-GT, GPT and/or GOT in baseline blood check
• Already diagnosed kidney dysfunction and/or increased or decreased creatinine, urea and/or uric acid in baseline blood check
• Medications that might affect the endpoints of the study e.g. immunosuppressive medication (cortisol, antibody treatment), hormone replacement therapy, medication for fat metabolism (e.g. statine, fibrate)
• Participation in another intervention study shorter than three months ago

Related Conditions & MeSH terms

• Body Composition, Beneficial
• Metabolic Diseases
• Obesity
• Obesity, Abdominal
• Visceral Obesity
• Weight Loss

Intervention

Other:
• Calorie Restriction
diet intervention to reduce the risk for obesity associated diseases

Locations

Country	Name	City	State
Germany	German Cancer Research Center	Heidelberg	Baden-Württemberg

Sponsors (2)

Lead Sponsor	Collaborator
German Cancer Research Center	University Hospital Heidelberg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in the composition of the gut microbiota by taxonomic, functional, and comparative analysis of sequencing data	Exploratory Outcome	Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Other	Changes in blood metabolites, as measured by LC-MS/MS-based targeted and untargeted metabolomics tools	Exploratory Outcome	Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Primary	Changes in gene expression in subcutaneous adipose tissue measured by whole genome sequencing		Assessments at baseline (week 0), and after the intervention phase (week 13)
Secondary	Changes in abdominal fat distribution pattern (visceral, subcutaneous, total adipose tissue) measured by magnetic resonance spectroscopy		Assessments at baseline (week 0), after the intervention phase (week 13),and after the follow-up phase (week 52)
Secondary	Changes in blood-based biomarkers, i.e. parameters of inflammation, adipokines, growth and hormonal factors, which have been shown to be associated with obesity-related chronic diseases before		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintenance phase (week 25), and after the maintenance phase (week 25)
Secondary	Changes in weight (kg)		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Secondary	Changes in BMI (kg/m2)		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Secondary	Changes in waist circumference (cm)		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Secondary	Changes in hip circumference (cm)		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Secondary	Changes in blood pressure (mm/Hg)		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Secondary	Changes in pulse (bpm)		Assessments at baseline (week 0), after the intervention phase (week 13), after the maintencance phase (week 25) and after the follow-up phase (week 52)
Secondary	Changes in quality of life (as defined by changes in SF-12-derived scores)		Assessments at baseline (week 0) and after the intervention phase (week 13)
Secondary	Changes in liver fat content measured by magnetic resonance spectroscopy		Assessments at baseline (week 0), after the intervention phase (week 13),and after the follow-up phase (week 52)